Formulation and pharmacological evaluation of anti-psoriatic gel of Rivea hypocrateriformis (Desr.) Choisy

Psoriasis is an auto-immune disease, which is characterized by dry skin and red patches all over the body and shedding resembling fish scales. The skin disease is accompanied by an Atopic type of dermatitis then eczema that may finally lead to a psoriatic condition. Rivea hypocrateriformis in Tamil is named as Bhodhi Keerai or Musutai Kodi. Among the aerial parts leafy portion was taken and dried in shade, coarsely powdered, and further research was carried out. Ethanolic extracts of leaves were prioritized for the research. Anatomical characters of leaves reveals the presence of Palisade, collenchyma, spongy parenchymatous cell with starch grains in entire mesophyll regions.Appressed covering trichomes are found in the upper and lower parts of the epidermis with the Paracytic type of stomata with aimed to correlate all the studies.Rivea hypocrateriformis reveals the presence of active constituents such as Phloretin, Hexadecanoic acid Rutinoside by GC-MS analysis,then by means of In silico screening it proves that Rutin binds with the protein IL2 and TNF alpha which exhibits the therapeutic benefits in curing skin diseases, anti-inflammation, anti-oxidant ,anti- cancer and various disease ailments.DNA barcoding performed for this species and compard with Rivea ornata and Rivea clarekinata by means of which the genes were authenticated and the species Rivea hypocrateriformis was identified. Gel was formulated with ethanolic leaf extract of Rivea hypocrateriformis,The Rivea hypocrateriformis gel at 100μg/mL substantially inhibits inducible nitric oxide synthetase enzyme and other inflammatory mediators which are responsible for swelling. Imiquimod-induced psoriatic activity in rats was performed with the Rivea hypocrateriformis gel in curing mild Atopic to severe psoriatic skin diseases.The regeneration of skin were examined which gives a prompt response at 400mg/kg of Rivea hypocrateriformis gel compared to 1% Salicylic acid, by declining the effects of Erythema, Induration, and Desquamation.